Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019148 · ClinicalTrials.gov registry record
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
A clinical trial of Epidermolysis Bullosa Dystrophica, sponsored by Stanford University.
- Recruiting
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT01019148 is a study of Epidermolysis Bullosa Dystrophica that is actively recruiting participants, run by Stanford University. The registered enrollment target is 70 participants, above the 24-participant average among 3 other Epidermolysis Bullosa Dystrophica trials with a reported enrollment target (192% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01019148, a study of Epidermolysis Bullosa Dystrophica, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
Conditions Studied
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-11-10 |
| Est. Completion | 2029-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01019148
The ClinicalTrials.gov registry entry for NCT01019148 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 24-participant average among 3 other Epidermolysis Bullosa Dystrophica trials with a reported enrollment target (192% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epidermolysis Bullosa Dystrophica appearing as the primary indexed condition, and to 0 interventions.
NCT01019148 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01019148 about?
NCT01019148 is a clinical study titled "Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa". Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics o...
What is the current status of trial NCT01019148?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2009-11-10. Estimated completion is 2029-12-31.
What conditions does trial NCT01019148 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa Dystrophica.
Who is sponsoring clinical trial NCT01019148?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01019148 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa Dystrophica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.